← Back to Search

MAPK Pathway Inhibitor

NST-628 for Cancer (NST-628 Trial)

Phase 1
Recruiting
Research Sponsored by Nested Therapeutics, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Part A: Subjects with any solid tumor with genetic alteration of or evidence of tumor dependence upon the RAS/MAPK pathway (subject to additional restrictions specified in the study protocol)
Part B: Subjects must be diagnosed with one of the following solid tumors harboring specified genetic alterations based on a validated local test
Must not have
A history or evidence of cardiovascular risk
Part B: prior treatment with any MEK or BRAF inhibitor
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 2 years
Awards & highlights

Summary

This trial will test the safety and effectiveness of a drug called NST-628 in adult patients with advanced solid tumors that have specific genetic mutations. The study will be done in two parts and will focus on

Who is the study for?
This trial is for adults with advanced solid tumors that have mutations in the MAPK pathway and who've run out of standard treatment options. It's open to those over 18 or at legal consent age, with certain types of genetic alterations like NRAS or BRAF mutations, and requires a confirmed diagnosis through tissue samples.Check my eligibility
What is being tested?
The study tests NST-628 oral tablets' safety and effectiveness on patients with specific solid tumors. It's an early-stage (Phase 1), non-randomized trial where all participants receive multiple doses of NST-628 to assess its impact on their cancer.See study design
What are the potential side effects?
Since this is a Phase 1 trial primarily focused on safety and dosage levels, specific side effects are not listed but may include typical reactions seen in cancer treatments such as fatigue, nausea, skin changes, or other organ-specific issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My tumor has a genetic change linked to the RAS/MAPK pathway.
Select...
My solid tumor has specific genetic changes.
Select...
I am at least 18 years old or of legal age to consent where the study is conducted.
Select...
I am mostly active and can care for myself, regardless of my cancer type.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of heart problems or am at risk for heart disease.
Select...
I have previously been treated with a MEK or BRAF inhibitor.
Select...
I am not pregnant or breastfeeding.
Select...
I haven't taken any targeted cancer drugs in the last 14 days.
Select...
I can take oral medications without any issues.
Select...
I do not have conditions that affect how my body absorbs pills.
Select...
I have a history of serious eye problems that could increase my risk of retinal vein occlusion.
Select...
I have brain metastases that haven't been treated or are causing symptoms.
Select...
I have not had lung inflammation or ILD in the past 6 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Part A and B: Evaluate the safety of NST-628 in patients with advanced solid tumors
Part A: Determine the recommended dose for expansion of NST-628
Part B: Evaluate objective tumor response rate
Secondary outcome measures
Part A and B: Characterize the pharmacokinetics of NST-628
Part A and B: Evaluate overall survival (OS)
Part A and B: Evaluate progression free survival (PFS)
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Part A Dose Escalation and Part B Dose ExpansionExperimental Treatment1 Intervention
Part A will evaluate the safety of NST-628 with advanced solid tumors and determine the recommended dose for expansion of NST-628. Part B will evaluate the objective tumor response rate in subjects with advanced solid tumors harboring specified genetic alterations receiving NST-628 and evaluate the safety of NST-628 in subjects with advanced solid tumors in cohorts defined below: i. Melanoma Cohorts Activating NRAS mutations Select BRAF alterations ii. Non-Melanoma Cohorts: Solid tumors with NRAS activating mutations Solid tumors with KRAS activating mutations Solid tumors with select BRAF alterations Glioma with BRAF alterations

Find a Location

Who is running the clinical trial?

Nested Therapeutics, IncLead Sponsor
~153 spots leftby Nov 2028